This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rollison, D. E. M. Articles by Major, E. O. Search for Related Content PubMed PubMed Citation Articles by Rollison, D. E. M. Articles by Major, E. O.

Serum Antibodies to JC Virus, BK Virus, Simian Virus 40, and the Risk of Incident Adult Astrocytic Brain Tumors¹

Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205 [D. E. M. R., K. J. H., A. J. A., S. H.]; Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205 [R. D., K. V. S.]; and National Institute of Neurological Disorders and Stroke, Bethesda, Maryland 20852 [J. H., E. O. M.]

Genomic sequences of the human polyomaviruses, JC virus (JCV) and BK virus (BKV), and simian virus 40 (SV40) have been reported from several types of human brain tumors, but there have been no population-based seroepidemiologic studies to evaluate the association between polyomavirus infection and brain tumors. We conducted a case-control study, nested within a prospective cohort, to investigate the association between antibodies to JCV, BKV, and SV40, as measured in serum collected 1–22 years before diagnosis and incident primary malignant brain tumors. Brain tumor cases (n = 44) and age-, gender-, and race-matched controls (n = 88) were identified from participants of two specimen banks in Washington County, Maryland. IgG antibodies to the capsid proteins of JCV and BKV were assessed using ELISAs. SV40-neutralizing antibodies were measured using plaque neutralization assays. Similar to the general population, the prevalence of JCV and BKV infection was high in our study population (77 and 85%, respectively). Antibodies to SV40 were less prevalent (11%). The odds ratio for subsequent brain tumor development was 1.46 [95% confidence interval (CI), 0.61–3.5] for JCV, 0.66 for BKV (95% CI, 0.22–1.95), and 1.00 for SV40 (95% CI, 0.30–3.32). Given the high prevalence of JCV and BKV infections and the millions who were potentially exposed to SV40 through contaminated polio vaccines, future studies should attempt to replicate these findings.

This article has been cited by other articles:

				P. S. Randhawa, G. Gupta, A. Vats, R. Shapiro, and R. P. Viscidi Immunoglobulin G, A, and M Responses to BK Virus in Renal Transplantation. Clin. Vaccine Immunol., September 1, 2006; 13(9): 1057 - 1063. [Abstract] [Full Text] [PDF]

				D. E. Rollison, E. A. Engels, N. A. Halsey, K. V. Shah, R. P. Viscidi, and K. J. Helzlsouer Prediagnostic Circulating Antibodies to JC and BK Human Polyomaviruses and Risk of Non-Hodgkin Lymphoma. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 543 - 550. [Abstract] [Full Text] [PDF]

				M. Wrensch, A. Weinberg, J. Wiencke, R. Miike, J. Sison, J. Wiemels, G. Barger, G. DeLorenze, K. Aldape, and K. Kelsey History of Chickenpox and Shingles and Prevalence of Antibodies to Varicella-Zoster Virus and Three Other Herpesviruses among Adults with Glioma and Controls Am. J. Epidemiol., May 15, 2005; 161(10): 929 - 938. [Abstract] [Full Text] [PDF]

				D. E. M. Rollison, W. F. Page, H. Crawford, G. Gridley, S. Wacholder, J. Martin, R. Miller, and E. A. Engels Case-Control Study of Cancer among US Army Veterans Exposed to Simian Virus 40-contaminated Adenovirus Vaccine Am. J. Epidemiol., August 15, 2004; 160(4): 317 - 324. [Abstract] [Full Text] [PDF]